Oxford BioDynamics (OBD) AI Stock Analysis

• Market Cap: £8.15M
• Dividend Yield: N/A
• Average Volume (3M): 21.87M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.61
• Revenue Growth: 72.17%
• EPS Growth: 79.03%
• Country: UK
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 4,290,911,000
• 10 Day Avg. Volume: 50,883,470
• 30 Day Avg. Volume: 21,870,725
• PEG Ratio: <0.01
• Price to Book (P/B): 5.90
• Price to Sales (P/S): 6.02
• P/FCF Ratio: -0.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): >-0.01
• Revenue Forecast (FY): £2.32M

• Rating: 40 Underperform
• Price Target: 0.19 p ▼(-20.83% Downside)
• Action: Downgraded Date: 03/21/26
• Date: Action: Downgraded 03/21/26

The score is driven primarily by very weak financial performance (losses, high leverage, and deteriorating free cash flow). Technicals also lean bearish with the stock trading below major moving averages, partially offset by oversold RSI. Valuation remains constrained because negative earnings make P/E less informative and there is no dividend yield provided.

Positive Factors

Proprietary EpiSwitch platform

Ownership of a proprietary epigenetic EpiSwitch platform provides a durable competitive advantage in biomarker discovery and diagnostics. The platform supports repeatable assays, licensing and partnership opportunities, raising barriers to entry and enabling long-term product and service roadmaps across oncology and autoimmune indications.

Negative Factors

High leverage

A debt-to-equity ratio of 4.58 signals heavy reliance on debt, which constrains financial flexibility and raises refinancing and interest-rate risk. High leverage can limit capacity to invest in commercialization or R&D, increase bankruptcy risk in stress, and amplify dilution if equity raises are required.

Oxford BioDynamics Business Overview & Revenue Model

Company Description

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technolog...

Read more

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technolog...

How the Company Makes Money

Oxford BioDynamics generates revenue through a combination of biomarker discovery services, partnerships with pharmaceutical and biotechnology companies, and the commercialization of its proprietary EpiSwitch technology. Key revenue streams includ...

Read more

Oxford BioDynamics generates revenue through a combination of biomarker discovery services, partnerships with pharmaceutical and biotechnology companies, and the commercialization of its proprietary EpiSwitch technology. Key revenue streams includ...

Oxford BioDynamics Financial Statement Overview

Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	1.09M	636.00K	510.00K	154.00K	341.00K
Gross Profit	-6.15M	289.00K	266.00K	116.00K	-557.00K
EBITDA	-9.80M	-10.27M	-9.84M	-6.16M	-6.43M
Net Income	-11.15M	-11.57M	-10.83M	-6.71M	-6.68M
Balance Sheet
Total Assets	8.09M	12.11M	16.13M	11.34M	15.38M
Cash, Cash Equivalents and Short-Term Investments	1.39M	2.83M	5.25M	999.00K	4.34M
Total Debt	5.11M	5.74M	6.44M	6.14M	6.59M
Total Liabilities	6.97M	7.75M	10.07M	8.76M	8.69M
Stockholders Equity	1.12M	4.36M	6.05M	2.59M	6.68M
Cash Flow
Free Cash Flow	-7.73M	-10.77M	-9.01M	-6.08M	-9.01M
Operating Cash Flow	-7.71M	-10.17M	-8.29M	-5.18M	-5.92M
Investing Cash Flow	756.00K	-1.49M	-691.00K	1.25M	2.83M
Financing Cash Flow	6.52M	8.25M	13.42M	2.56M	-804.00K

Oxford BioDynamics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBD, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.21, below the 50-day MA of 0.25, and below the 200-day MA of 0.35, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 34.09 is Neutral, neither overbought nor oversold. The STOCH value of 40.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBD.

Oxford BioDynamics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IXI	51 Neutral	£6.83M	-7.18	-15.57%	―	13.32%	55.07%
GENF	47 Neutral	£10.45M	-1.89	377.33%	―	―	―
FAB	44 Neutral	£17.82M	-9.67	-210.32%	―	-11.43%	23.40%
SBTX	44 Neutral	£25.27M	-54.98	-10.01%	―	283.74%	78.57%
OBD	40 Underperform	£8.15M	-0.25	-316.67%	―	72.17%	79.03%
APTA	40 Underperform	£18.29M	-6.19	-213.66%	―	39.88%	81.33%

Oxford BioDynamics Corporate Events